GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases.
Company profile
Ticker
GNFT, GNFTF
Exchange
Website
CEO
Pascal Prigent
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
GNFT stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
28 Feb 23
6-K
Current report (foreign)
30 Jan 23
6-K
GENFIT Announces 2023 Financial Calendar
24 Jan 23
6-K
GENFIT to Participate in Upcoming Investor Conferences
5 Jan 23
6-K
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
17 Nov 22
6-K
GENFIT Reports Third Quarter 2022 Financial Information
10 Nov 22
6-K
Current report (foreign)
25 Oct 22
6-K
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis
29 Sep 22
6-K
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
28 Sep 22
6-K
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
19 Sep 22
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Institutional ownership, Q3 2022
4.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 16 |
| Opened positions | 6 |
| Closed positions | 4 |
| Increased positions | 2 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 8.21 mm |
| Total shares | 2.25 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Tang Capital Management | 1.20 mm | $4.37 mm |
| Adage Capital Partners GP, L.L.C. | 516.06 k | $1.88 mm |
| DAFNA Capital Management | 187.94 k | $686.00 k |
| Two Sigma Investments | 64.73 k | $236.00 k |
| Millennium Management | 57.73 k | $211.00 k |
| MS Morgan Stanley | 56.93 k | $208.00 k |
| O'shaughnessy Asset Management | 51.00 k | $186.00 k |
| Citadel Advisors | 35.32 k | $129.00 k |
| Ritholtz Wealth Management | 29.70 k | $108.00 k |
| Envestnet Asset Management | 19.10 k | $70.00 k |